Role of cyclooxygenase-2 in myocardial infarction and ischaemia

Journal of the College of Physicians and Surgeons Pakistan

Volumn 16, Issue 5, 2006, Pages 324-328

  Saeed, Sheikh Arshad ^a   Ahmed, Sagheer ^b  

^a UNIVERSITY OF KARACHI   (Pakistan)

^b AGA KHAN UNIVERSITY   (Pakistan)

Author keywords

Cyclooxygenase 2; Histopathology; Hydrochloride; Isoprenaline; Myocardial infarction; Nimesulide; Rabbit heart model

Indexed keywords

CYCLOOXYGENASE 2; NIMESULIDE; PROSTAGLANDIN SYNTHASE INHIBITOR; SULFONAMIDE;

ANIMAL; ARTICLE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; PATHOLOGY; PHYSIOLOGY; RABBIT;

ANIMALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; RABBITS; SULFONAMIDES;

EID: 34147169390     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Mukerjee D. Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. Biochem Pharmacol 2002; 63: 817-821
2. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR study group. N Engl J Med 2000; 243: 1520-1528
3. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study. A randomized control trial. Celecoxib long-trem arthritis safety study. JAMA 2000; 284: 1247-1255
4. Mukerjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 954-959
5. Saeed SA, Gilani AH, Sultan BH, Karim RM, Shah BH. Myocardial ischemia and infarction in isoprenaline-treated rabbits: role of cyclooxygenases. Bichem Soc Trans 1998; 26: S342.
6. Adams JE 3rd, Bodor GS, Davila-Roman VG, Delmez JA, Apple FS, Ladenson JH, et al. Cardiac troponin I: a marker with high specificity for cardiac injury. Circulation 1993; 88: 101-106
7. Rosalki SB. An improved procedure for serum creatine phosphokinase determination. J Lab Clin Med 1967; 69: 696-705.
8. Langedorff. Pfluners Arch Ges Physiol 1895; 190: 280.
9. Bonow RO, Lipson LC, Shaheen FH, Capurro NL, Inser JM, Roberst WC, et al. Lack of effect of aspirin on myocardial infarct size in dogs. Am J Cardiol 1981; 47: 258-264
10. Mobert J, Becker BF. Cyclooxygenase inhibition aggravates ishemia-reperfuion injury in the perfused guinea pig heart: involvement of isoprostanes. J Am Coll Cardiol 1998; 31:1687-1694
11. Lecomte M, Laneuville O, Ji C, DeWitt DL, Smith WL. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J Biol Chem 1994; 269: 13207-13215
12. Saito T, Rodger IW, Hu F, Shennib H, Giaid A. Inhibition of cyclooxygenase-2 improves cardiac function in myocardial infarction. Biochem Biophys Res Commun 2000; 273: 772-775
13. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2 dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102: 840-845
14. Baker CS, Hall RJ, Evans TJ, Pomerance A, Maclouf J, Creminon C, et al. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalized with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol 1999; 19: 646-655
15. Schonbeck U, Sukhova GK, Graber P, Coulter S, Libby P. Augmented expressoin of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 1999; 155: 1281-1291
16. Koenig W. Inflammation and coronary heart disease: an overview. Caridol Rev 2001; 9: 31-35
17. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular disease: the role of oxidant stress. Circ Res 2000; 87: 840-844
18. O'Banion MK. Cyclooxygenase-2: molecular biology, pharmacology and neurobiology. Critc Rev Neurobiol 1999; 13: 45-82.
19. Heitzer T, Just H, Munzel T. Antioxidant vitamin C improves and endothelial dysfunction in chronic smokers. Circulation 1996; 94: 6-9.
20. Chenevard R, Hurlimann D, Bechir M, Enseleit F, Spieker L, Hermann M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003; 107: 405-409
21. Verma S, Raj SR, Shewchuk L, Mather KJ, Anderson TJ. Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: randomized evaluation of rofecoxib versus naproxen on endothelium-dependent vasodilatation. Circulation 2001; 104: 2879-2882
22. Damron DS, Summers BA. Arachidonic acid enhances contraction and intracellular Ca2+ transients in individual rat ventricular myocytes. Am J Physiol 272: H350-9.
23. Schrör K, Hohlfeld T. Inotropic actions of eicosanoids. Basic Res Cardiol 1992; 87: 2-11.
24. Seibert K, Zhang Y, Leahy K, Hauser S. Masferrer J, Perkins W, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase-2 in inflammation and pain. Proc Natl Acad Sci USA 1994; 25: 12013-12017
25. Agha AM, El-Khatib AS, Al-Zuhair H. Modulation of oxidant status by meloxicam in experimentally induced arthritis. Pharmacol Res 1999; 40: 385-392
26. Goldhaber JI, Qayyum MS. Oxygen free radicals and excitation-contraction coupling. Antioxid Redox Signal 2000. 2: 55-64.
27. Patrono C, Fitzgerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arteriosclat Thromb Vasc Biol 1997; 17: 2309-2315
28. Takahashi K, Nammour TM, Fukunaga M, Ebert J, Morrow JD, Robert LJ, et al. Glomerular actions of a free radical-generated novel prostaglandin, 8-epiprostaglandin f2 alpha, in the rat. Evidence for interaction with thromboxane A2 receptors. J Clin Invest 1992; 90: 136-141